October 12, 2015
NEW YORK, Oct. 9, 2015 /PRNewswire-iReach/ -- River Vision Development Corp. (RVDC) today announced the completion of enrollment of a Phase 2 clinical study of RV001 (teprotumumab) for the treatment of Graves' Orbitopathy (GO). RV001 is a fully human IGF-1 receptor antagonist antibody with a safety database comprised of more than 700 cancer patients. The study is being conducted at 15 sites...


Danish researchers provide proof: Caesarean sections can lead to asthma and allergies
12. November 2020
Brand-new medical treatment for cocaine addiction
10. November 2020
90 million to 18 Talented Researchers
19. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge